Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to help manufacture its medicines in the US, as the threat of tariffs looms over the nation’s drug supply.

Regeneron Pharmaceuticals, Inc. (REGN) announced on Tuesday that it has entered into a manufacturing and supply agreement with contract biopharmaceutical manufacturer FUJIFILM Diosynth Biotechnologies,

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity. Valued at more than $3bn, the partnership is set to almost double Regeneron's manufacturing capacity in the US by using Fujifilm's new biopharmaceutical facility in Holly Springs,